Vanguard Global Advisers’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.55M Buy
19,258
+257
+1% +$55.9K ﹤0.01% 923
2026
Q2
$4.65M Buy
19,001
+646
+4% +$140K ﹤0.01% 822
2026
Q1
$3.1M Buy
+18,355
New +$3.17M ﹤0.01% 951

Other funds holding AXSM

Vanguard Global Advisers's AXSM Position: Q3 2026 in Review

Vanguard Global Advisers increased its Axsome Therapeutics (AXSM) stake by 1.4% in Q3 2026, buying an estimated $55.9K and bringing the position to 19,258 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #923.

Vanguard Global Advisers first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.65M in Q2 2026. 459 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Vanguard Global Advisers held 19,258 shares of Axsome Therapeutics worth $3.55M as of Q3 2026.
  • Vanguard Global Advisers bought 257 Axsome Therapeutics shares in Q3 2026, an estimated $55.9K.
  • Axsome Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #923 holding.
  • Vanguard Global Advisers first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Axsome Therapeutics position peaked at $4.65M in Q2 2026.
  • 459 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.